Results 301 to 310 of about 268,746 (338)
Some of the next articles are maybe not open access.
Immune Checkpoint Inhibitor Toxicity
Current Oncology Reports, 2018Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire +2 more sources
Immune checkpoint inhibitor myocarditis
Current Opinion in Cardiology, 2019The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire +2 more sources
Immune Checkpoint Inhibitor-Associated Nephrotoxicity
Nephron, 2023<b><i>Context:</i></b> The clinical indications for immune checkpoint inhibitors (ICIs) are rapidly expanding. However, adverse events affecting multiple organs, including kidneys leading to ICI-associated acute kidney injury (AKI), remain a significant challenge with ICI therapy.
Omar Mamlouk, Farhad R. Danesh
openaire +2 more sources
Immune checkpoint inhibitors: current status
BMJ Supportive & Palliative Care, 2021The use of immune checkpoint inhibitors (ICIs) is growing rapidly in oncology and palliative care clinicians and other generalists will increasingly see patients who are receiving, or who have received ICI. For optimal care, it is important that clinicians have a basic understanding of the unique nature of ICI as anticancer treatments, including ...
Ana Filipa Palma dos Reis +2 more
openaire +2 more sources
Immune checkpoint inhibitor-related hypophysitis
Best Practice & Research Clinical Endocrinology & Metabolism, 2022Immune checkpoint inhibitors (ICIs) have been recently proposed as a strategy for treating anti-malignant neoplasms. However, this treatment leads to immune-related adverse events (irAEs) such as autoimmune endocrinopathy. Early diagnosis and appropriate treatment of ICI-related hypophysitis are essential as it can manifest as a life-threatening ...
Tadashi, Mizukoshi +2 more
openaire +2 more sources
Radiotherapy, immunity, and immune checkpoint inhibitors
The Lancet OncologyRadiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch +2 more
openaire +2 more sources
Immune Checkpoint Inhibitor–Induced Lipodystrophy
JAMA DermatologyThis case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.
Riganti J. +15 more
openaire +3 more sources